115 related articles for article (PubMed ID: 17878619)
1. [Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution)].
Watanabe M; Kodama H; Hasegawa K; Itoh K
Nihon Yakurigaku Zasshi; 2007 Sep; 130(3):221-31. PubMed ID: 17878619
[No Abstract] [Full Text] [Related]
2. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
[TBL] [Abstract][Full Text] [Related]
3. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.
Abelson MB; Gomes PJ
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):453-61. PubMed ID: 18433347
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
Abelson MB; Welch DL
Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
[TBL] [Abstract][Full Text] [Related]
5. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
Ohmori K; Hasegawa K; Tamura T; Miyake K; Matsubara M; Masaki S; Karasawa A; Urayama N; Horikoshi K; Kajita J; Hasegawa M; Taniguchi K; Komada T; Kawamoto Y
Arzneimittelforschung; 2004; 54(12):809-29. PubMed ID: 15646365
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
[TBL] [Abstract][Full Text] [Related]
7. A review of olopatadine for the treatment of ocular allergy.
Abelson MB
Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
[TBL] [Abstract][Full Text] [Related]
8. Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model.
Novack GD
Clin Ther; 2002 Sep; 24(9):1477-8; author reply 1478-80. PubMed ID: 12380639
[No Abstract] [Full Text] [Related]
9. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
Mah FS; O'Brien T; Kim T; Torkildsen G
Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
[TBL] [Abstract][Full Text] [Related]
10. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
11. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
Artal MN; Luna JD; Discepola M
Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive review of olopatadine: the molecule and its clinical entities.
Kaliner MA; Oppenheimer J; Farrar JR
Allergy Asthma Proc; 2010; 31(2):112-9. PubMed ID: 20406593
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
Aguilar AJ
Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug].
Ohmori K; Ikemura T; Kobayashi H; Mukouyama A
Nihon Yakurigaku Zasshi; 2001 Jul; 118(1):51-8. PubMed ID: 11496828
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S
Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265
[TBL] [Abstract][Full Text] [Related]
17. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy.
Brodsky M
Acta Ophthalmol Scand Suppl; 2000; (230):56-9. PubMed ID: 11057353
[TBL] [Abstract][Full Text] [Related]
18. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
Schoch C
Ocul Immunol Inflamm; 2005 Feb; 13(1):39-44. PubMed ID: 15804768
[TBL] [Abstract][Full Text] [Related]
19. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
[TBL] [Abstract][Full Text] [Related]
20. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
Lytinas M; Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Allergy Asthma Proc; 2002; 23(1):45-51. PubMed ID: 11894734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
